# CAM



Evidence-Based Complementary and Alternative Medicine

# Natural Products as Sources of Antimalarial Drugs

Lead Guest Editor: Philip F. Uzor Guest Editors: Vivitri D. Prasasty and Chukwuma O. Agubata

# Natural Products as Sources of Antimalarial Drugs

Lead Guest Editor: Philip F. Uzor Guest Editors: Vivitri D. Prasasty and Chukwuma O. Agubata

Copyright © 2020 Hindawi Limited. All rights reserved.

This is a special issue published in "Evidence-Based Complementary and Alternative Medicine." All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **Editorial Board**

Mona Abdel-Tawab, Germany Rosaria Acquaviva, Italy Gabriel A. Agbor, Cameroon Ulysses Paulino Albuquerque, Brazil Samir Lutf Aleryani, USA Mohammed S. Ali-Shtayeh, Palestinian Authority Gianni Allais, Italy Terje Alraek, Norway Adolfo Andrade-Cetto, Mexico Isabel Andújar, Spain Letizia Angiolella, Italy Makoto Arai, Japan Hyunsu Bae, Republic of Korea Onesmo B. Balemba, USA Winfried Banzer, Germany Samra Bashir, Pakistan Jairo Kenupp Bastos, Brazil Arpita Basu, USA Daniela Beghelli, Italy Juana Benedí, Spain Bettina Berger, Germany Maria Camilla Bergonzi, Italy Andresa A. Berretta, Brazil Anna Rita Bilia, Italy Monica Borgatti, Italy Francesca Borrelli, Italy Gioacchino Calapai, Italy Giuseppe Caminiti, Italy Raffaele Capasso, Italy Francesco Cardini, Italy Pierre Champy, France Shun-Wan Chan, Hong Kong Kevin Chen, USA Evan P. Cherniack, USA Salvatore Chirumbolo, Italy Jae Youl Cho, Republic of Korea Kathrine Bisgaard Christensen, Denmark Shuang-En Chuang, Taiwan Yuri Clement, Trinidad And Tobago Ian Cock, Australia Marisa Colone, Italy

Lisa A. Conboy, USA Kieran Cooley, Canada Edwin L. Cooper, USA Maria T. Cruz, Portugal Roberto K. N. Cuman, Brazil Ademar A. Da Silva Filho, Brazil Giuseppe D'Antona, Italy Vincenzo De Feo, Italy Rocío De la Puerta, Spain Laura De Martino, Italy Antonio C. P. de Oliveira, Brazil Arthur De Sá Ferreira, Brazil Nunziatina De Tommasi, Italy Alexandra Deters, Germany Farzad Deyhim, USA Claudia Di Giacomo, Italy Antonella Di Sotto, Italy Luciana Dini, Italy Caigan Du, Canada Jeng-Ren Duann, USA Nativ Dudai, Israel Thomas Efferth, Germany Abir El-Alfy, USA Giuseppe Esposito, Italy Keturah R. Faurot, USA Yibin Feng, Hong Kong Nianping Feng, China Antonella Fioravanti, Italy Johannes Fleckenstein, Germany Filippo Fratini, Italy Brett Froeliger, USA Jian-Li Gao, China Dolores García Giménez, Spain Gabino Garrido, Chile Ipek Goktepe, Qatar Yuewen Gong, Canada Susana Gorzalczany, Argentina Sebastian Granica, Poland Settimio Grimaldi, Italy Maruti Ram Gudavalli, USA Narcís Gusi, Spain Svein Haavik, Norway

Solomon Habtemariam, United Kingdom Michael G. Hammes, Germany Kuzhuvelil B. Harikumar, India Ken Haruma, Japan Thierry Hennebelle, France Markus Horneber, Germany Ching-Liang Hsieh, Taiwan Benny T. K. Huat, Singapore Ciara Hughes, Ireland Attila Hunyadi, Hungary H. Stephen Injeyan, Canada Chie Ishikawa, Japan Angelo A. Izzo, Italy G. K. Jayaprakasha, USA Leopold Jirovetz, Austria Takahide Kagawa, Japan Atsushi Kameyama, Japan Wenyi Kang, China Shao-Hsuan Kao, Taiwan Juntra Karbwang, Japan Teh Ley Kek, Malaysia Deborah A. Kennedy, Canada Cheorl-Ho Kim, Republic of Korea Youn-Chul Kim, Republic of Korea Yoshiyuki Kimura, Japan Toshiaki Kogure, Japan Jian Kong, USA Tetsuya Konishi, Japan Karin Kraft, Germany Omer Kucuk, USA Victor Kuete, Cameroon Yiu-Wa Kwan, Hong Kong Kuang C. Lai, Taiwan Ilaria Lampronti, Italy Lixing Lao, Hong Kong Mario Ledda, Italy Christian Lehmann, Canada George B. Lenon, Australia Marco Leonti, Italy Lawrence Leung, Canada Min Li, China XiuMin Li, Armenia Chun-Guang Li, Australia Giovanni Li Volti, Italy Ho Lin, Taiwan Bi-Fong Lin, Taiwan Kuo-Tong Liou, Taiwan

Christopher G. Lis, USA Gerhard Litscher, Austria I-Min Liu, Taiwan Monica Loizzo, Italy Víctor López, Spain Anderson Luiz-Ferreira, Brazil Thomas Lundeberg, Sweden Michel Mansur Machado, Brazil Filippo Maggi, Italy Valentina Maggini, Italy Jamal A. Mahajna, Israel Juraj Majtan, Slovakia Toshiaki Makino, Japan Nicola Malafronte, Italy Francesca Mancianti, Italy Carmen Mannucci, Italy Arroyo-Morales Manuel, Spain Fatima Martel, Portugal Simona Martinotti, Italy Carlos H. G. Martins, Brazil Stefania Marzocco, Italy Andrea Maxia, Italy James H. Mcauley, Australia Kristine McGrath, Australia James S. McLay, United Kingdom Lewis Mehl-Madrona, USA Ayikoé Guy Mensah-Nyagan, France Oliver Micke, Germany Maria G. Miguel, Portugal Luigi Milella, Italy Roberto Miniero, Italy Letteria Minutoli, Italy Albert Moraska, USA Giuseppe Morgia, Italy Mark Moss, United Kingdom Yoshiharu Motoo, Japan Kamal D. Moudgil, USA Yoshiki Mukudai, Japan Sakthivel Muniyan, USA Massimo Nabissi, Italy Hajime Nakae, Japan Takao Namiki, Japan Srinivas Nammi, Australia Krishnadas Nandakumar, India Vitaly Napadow, USA Michele Navarra, Italy Isabella Neri, Italy

Pratibha V. Nerurkar, USA Marcello Nicoletti, Italy Cristina Nogueira, Brazil Martin Offenbaecher, Germany Yoshiji Ohta, Japan Olumayokun A. Olajide, United Kingdom Ester Pagano, Italy Sokcheon Pak, Australia Siyaram Pandey, Canada Visweswara Rao Pasupuleti, Malaysia Bhushan Patwardhan, India Claudia Helena Pellizzon, Brazil Raffaele Pezzani, Italy Florian Pfab, Germany Sonia Piacente, Italy Andrea Pieroni, Italy Richard Pietras, USA Andrew Pipingas, Australia Haifa Qiao, USA Xianqin Qu, Australia Roja Rahimi, Iran Khalid Rahman, United Kingdom Elia Ranzato, Italy Ke Ren, USA Man Hee Rhee, Republic of Korea Daniela Rigano, Italy José L. Rios, Spain Barbara Romano, Italy Mariangela Rondanelli, Italy Omar Said, Israel Avni Sali, Australia Mohd. Zaki Salleh, Malaysia Andreas Sandner-Kiesling, Austria Manel Santafe, Spain Tadaaki Satou, Japan Michael A. Savka, USA Roland Schoop, Switzerland Sven Schröder, Germany Veronique Seidel, United Kingdom Senthamil R. Selvan PhD, USA Hongcai Shang, China Ronald Sherman, USA Karen J. Sherman, USA Yukihiro Shoyama, Japan Morry Silberstein, Australia Kuttulebbai N. S. Sirajudeen, Malaysia Francisco Solano, Spain

Chang G. Son, Republic of Korea Annarita Stringaro, Italy Shan-Yu Su, Taiwan Orazio Taglialatela-Scafati, Italy Takashi Takeda, Japan Ghee T. Tan, USA Norman Temple, Canada Mencherini Teresa, Italy Mayank Thakur, Germany Menaka C. Thounaojam, USA Evelin Tiralongo, Australia Michał Tomczyk, Poland Loren Toussaint, USA Luigia Trabace, Italy Yew-Min Tzeng, Taiwan Dawn M. Upchurch, USA Konrad Urech, Switzerland Takuhiro Uto, Japan Patricia Valentao, Portugal Sandy van Vuuren, South Africa Luca Vanella, Italy Alfredo Vannacci, Italy Antonio Vassallo, Italy Miguel Vilas-Boas, Portugal Aristo Vojdani, USA Almir Gonçalves Wanderley, Brazil Chong-Zhi Wang, USA Shu-Ming Wang, USA Jonathan L. Wardle, Australia Kenji Watanabe, Japan Jintanaporn Wattanathorn, Thailand Silvia Wein, Germany Janelle Wheat, Australia Jenny M. Wilkinson, Australia Christopher Worsnop, Australia Haruki Yamada, Japan Nobuo Yamaguchi, Japan Junqing Yang, China Ling Yang, China Albert S. Yeung, USA Armando Zarrelli, Italy Chris Zaslawski, Australia Suzanna M. Zick, USA

# **Contents**

#### Natural Products as Sources of Antimalarial Drugs

Philip F. Uzor (D, Vivitri D. Prasasty, and Chukwuma O. Agubata Editorial (2 pages), Article ID 9385125, Volume 2020 (2020)

#### Effect of Formulated Artocarpus champeden Extract on Parasite Growth and Immune Response of **Plasmodium berghei-Infected Mice**

A. Widyawaruyanti D, N. Harwiningtias, L. Tumewu, A.F. Hafid, and Soetjipto Research Article (7 pages), Article ID 4678634, Volume 2020 (2020)

#### Alkaloids from Plants with Antimalarial Activity: A Review of Recent Studies

Philip F. Uzor Review Article (17 pages), Article ID 8749083, Volume 2020 (2020)

In Vitro Antiplasmodium and Chloroquine Resistance Reversal Effects of Andrographolide Zaid O. Ibraheem 🝺, Roslaini Abd Majid 🝺, Hasidah Mohd Sidek 🝺, Sabariah Md Noor 🝺, Mun Fei Yam (b), Mohammad Faruq Abd Rachman Isnadi (b), and Rusliza Basir (b) Research Article (16 pages), Article ID 7967980, Volume 2019 (2019)

Various Parts of Helianthus annuus Plants as New Sources of Antimalarial Drugs Wiwied Ekasari , Dwi Widya Pratiwi, Zelmira Amanda, Suciati, Aty Widyawaruyanti , and Heny Arwati

Research Article (7 pages), Article ID 7390385, Volume 2019 (2019)

#### Evaluation of the Bioactivities of Rumex crispus L. Leaves and Root Extracts Using Toxicity, Antimicrobial, and Antiparasitic Assays

Oladayo Amed Idris (D, Olubunmi Abosede Wintola (D, and Anthony Jide Afolayan Research Article (13 pages), Article ID 6825297, Volume 2019 (2019)

Exploring Antimalarial Herbal Plants across Communities in Uganda Based on Electronic Data Denis Okello (D) and Youngmin Kang (D) Review Article (27 pages), Article ID 3057180, Volume 2019 (2019)

```
Phytochemical Constituents, Antioxidant, Cytotoxicity, Antimicrobial, Antitrypanosomal, and
Antimalarial Potentials of the Crude Extracts of Callistemon citrinus
Rotimi Larayetan (D), Zacchaeus S. Ololade, Oluranti O. Ogunmola, and Ayodele Ladokun
Research Article (14 pages), Article ID 5410923, Volume 2019 (2019)
```

#### Antimalarial Activity of Cordia africana (Lam.) (Boraginaceae) Leaf Extracts and Solvent Fractions in Plasmodium berghei-Infected Mice

Dawit Zewdu Wondafrash [D], Dayananda Bhoumik [D], Birhanetensay Masresha Altaye [D], Helen Bitew Tareke (D), and Brhane Teklebrhan Assefa Research Article (14 pages), Article ID 8324596, Volume 2019 (2019)



### Research Article

# Various Parts of *Helianthus annuus* Plants as New Sources of Antimalarial Drugs

# Wiwied Ekasari <sup>(b)</sup>, <sup>1</sup> Dwi Widya Pratiwi, <sup>1</sup> Zelmira Amanda, <sup>1</sup> Suciati, <sup>1</sup> Aty Widyawaruyanti <sup>(b)</sup>, <sup>1</sup> and Heny Arwati<sup>2</sup>

<sup>1</sup>Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia <sup>2</sup>Department of Medical Parasitology, Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia

Correspondence should be addressed to Wiwied Ekasari; wiwied-e@ff.unair.ac.id

Received 27 June 2019; Revised 16 October 2019; Accepted 11 November 2019; Published 26 November 2019

Guest Editor: Philip F. Uzor

Copyright © 2019 Wiwied Ekasari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Background*. Each part of *H. annuus* plants is traditionally used as medicinal remedies for several diseases, including malaria. Antimalarial activity of the leaf and the seed has already been observed; however, there is no report about antimalarial activity of the other parts of *H. annuus* plants. In this study, we assess *in vitro* and *in vivo* antimalarial activity of each part of the plants and its mechanism as antimalarial agent against inhibition of heme detoxification. *Objective*. To investigate the antimalarial activity against plasmodium falciparum 3D7 strain (chloroquine-sensitive), *in vivo* antimalarial activity against *P. berghei* using Peters' 4-day suppressive test in BALB/c mice, curative and prophylaxis assay, and inhibition of heme detoxification by evaluating  $\beta$ -hematin level. *Results*. Ethanol extract of the roots showed the highest antimalarial activity, followed by ethanol extract of leaves, with IC<sub>50</sub> values of 100 mg/kg, respectively. Ethanol extract of roots produced an ED<sub>50</sub> value of 10.6 ± 0.2 mg/kg in the curative test and showed an inhibition of 79.2% at a dose of 400 mg/kg in the prophylactic assay. In inhibition of heme detoxification assay, root and leaf ethanol extracts yielded a lower IC<sub>50</sub> value than positive (chloroquine) control with a value of 0.4 ± 0.0 and 0.5 ± 0.0 mg/mL, respectively. *Conclusion*. There were promising results of the ethanol extracts of root of *H. annuus* as a new source for the development of a new plant-based antimalarial agent.

#### 1. Introduction

Most developing countries, including Indonesia, still depend on using plants in traditional medicine, including antimalarial agents. One of these plants is *Helianthus annuus* (Asteraceae), known as sunflower or "*bunga matahari*" in local language. Traditionally, each part of *H. annuus* plants is widely used in several healthcare applications, including the treatment of malaria. Sunflower tea is reported to be useful in the treatment of malarial and lung disease [1], and the leaves have long been used in infusion and decoction as traditional remedy for malaria by Ambalabe village community, Madagascar [2].

Muti'ah et al. [3] report that 80% ethanol extract of *H. annuus* leaf shows good antimalarial activity with an  $ED_{50}$ 

value of 4.64 mg/kg. Moreover, the combination of 80% ethanol extract of *H. annuus* leaf and *Acalypha indica* Linn. leads to synergetic effect in *in vivo* antimalarial assay with a CI value of 0.46 (CI < 1) and an ED<sub>50</sub> value of 1.23 mg/kg [4]. Intisar et al. [5] also report that methanol and petroleum ether extract from *H. annuus* seeds showed good inhibition activity against *P. falciparum* strain KI with an EC<sub>50</sub> of 0.19 and 0.34 µg/mL, respectively.

Based on the data above, it is recognized that *H. annuus* plants are potential source of antimalarial drugs. However, antimalarial activity of the other parts of *H. annuus* plants has not been reported to date. Thus, in this study, we assess *in vitro* and *in vivo* antimalarial activity of each part of the plant and its mechanism as antimalarial agent against the inhibition of heme detoxification. The inhibition of heme

detoxification leads to growth disorder and malaria parasites' mortality as a result of membrane lysis and activity disorder of some enzymes [6–9]. Hence, a substance with high heme detoxification inhibition activity is considered a potential antimalarial agent. Inhibition of heme detoxification is one of the potential biochemical targets, which is possessed by chloroquine and artemisinin [10, 11]. The highest antimalarial activity of *H. annuus* plant parts and its ability to inhibit heme detoxification are expected to be obtained through this study as it can be a new source of antimalarial drugs.

#### 2. Materials and Methods

2.1. Plant Materials. H. annuus plants were obtained from Oro-oro Ombo, Malang, East Java, Indonesia, in November 2016, and determined by Materia Medica Batu, Malang, East Java. Each part of the plant, including roots, stems, seeds, flowers, and leaves, were air-dried separately. Samples were then ground to powder, once they are completely dried.

2.2. Animal Model. Adult male BALB/c mice with 20–30 g of bodyweight were obtained from Faculty of Veterinary Medicine, Universitas Airlangga. The mice were fed with mice pellet diet and given free access to drink clean water. The animals were allowed to acclimatize for two weeks before being treated. The permission and approval for animal studies were obtained from Faculty of Veterinary Medicine, Universitas Airlangga.

2.3. Preparation of 96% Ethanol Extract of H. annuus. Powders from each part of H. annuus plants (50 gram) were macerated by 96% ethanol and then evaporated on a rotary evaporator.

2.4. In Vitro Antimalarial Assay. In this research, cultures of Plasmodium falciparum strain 3D7 (chloroquine-sensitive) were used and cultivated using the Trager and Jensen method [12]. Cultures were cultivated in human  $O^+$  red blood cells with 5% hematocrit in RPMI 1640 (Gibco BRL, USA) added with 22.3 mM HEPES (Sigma), hypoxanthine, sodium bicarbonate, and 10% human  $O^+$  plasma. Chloroquine diphosphate was used as the positive control.

Antimalarial assay was done using a 24-well microplate with 1% initial and experimental parasitaemia (1 mL/well of suspension), followed by incubation in a multigas incubator at 37°C for 48 hours. The incubated materials were then collected and used to make a thin smear in a glass slide, fixated in methanol, and stained with Giemsa. The number of parasites was then observed under a microscope and compared with the negative control to determine the percentage of parasite growth inhibition.  $IC_{50}$  value was calculated using Probit Analysis.

2.5. In Vivo Antimalarial Activity Assay. Plasmodium berghei strain ANKA was obtained from Eijkman Institute of Molecular Biology, Jakarta, Indonesia. About 20% of parasitaemia-infected mice were dissected and then the intracardial blood was taken and diluted with the PBS. Each mouse used in this research was inoculated priorly intraperitoneally with 0.2 mL of solution containing  $1 \times 10^7$  *P. berghei*-infected erythrocytes [13].

In vivo antimalarial assay of the plant extract was done using Peter's method [14], which had been modified with 100 mg/kg/day as the selected dose. Thirty-six adult male BALB/c mice  $(25 \text{ g} \pm 3)$  were inoculated with parasites and randomly grouped into six groups (five treatment groups and one control group), with six mice in each group. Negative control group was treated with 0.5% sodium carboxymethyl cellulose (Na CMC) suspension. Treatment groups were treated with extract suspension of each part of the plant with the selected dose. Suspension was given orally once a day for 4 days. On the fourth day, a thin blood smear was made from the tail of each mouse, fixated in methanol, and then stained with Giemsa. The thin blood smears were then observed under a microscope to calculate the percentage of parasitaemia and parasite inhibition.

2.6. In Vivo Curative Assay of 96% Ethanol Extract of *H. annuus Roots.* Thirty adult male BALB/c mice (8 weeks old) were randomly divided into five groups (six mice per group). Each mouse was infected intraperitoneally with 0.2 mL of solution containing  $1 \times 10^7$  *P. berghei*-infected erythrocytes. Negative control (group 1) was treated with 0.5% Na CMC suspension. Groups 2, 3, 4, and 5 were treated with 96% ethanol extract suspension of *H. annuus* root with 1, 10, 100, and 250 mg/kg dose per mouse. Suspension was given orally once a day for 4 days. Percentage of parasitaemia was calculated by making a thin blood smear on the fourth day, which is then fixated in methanol and stained with Giemsa. The calculation was then compared with the control group. ED<sub>50</sub> value was obtained by using Probit Analysis.

2.7. In Vivo Prophylaxis Assay of 96% Ethanol Extract of H. annuus Roots. Thirty adult male BALB/c mice (8 weeks old) were randomly grouped into six groups (five mice per group). Groups 1, 2, 3, and 4 were treated with 96% ethanol extract suspension of H. annuus root with 100, 200, 400, and 800 mg/kg dose per mouse. Group 5 as the negative control group was treated with 0.5% Na CMC suspension, while the positive control (group 6) was given 13 mg/kg of doxycycline suspension [15]. Each suspension was given orally once a day for 4 days. On the fourth day, each mouse was inoculated with 0.2 mL of solution containing  $1 \times 10^7$  P. berghei-infected erythrocytes by intraperitoneal injection. Percentage of parasitaemia was determined on the third day by observing the thin blood smear and compared with the control group. Mean survival time of mice in each group was determined during 14 days ( $D_0-D_{13}$ ). Mean survival time was calculated using the following equation:

mean survival time (MST) = 
$$\frac{\text{sum of survival days}}{\text{total observation days}(14)} \times 100.$$

Evidence-Based Complementary and Alternative Medicine

2.8. Heme Detoxification Inhibition Assay. Inhibition of heme detoxification was assessed using the Basilico method [16] with modification. The extract and positive control (chloroquine diphosphate) were diluted with dimethyl sulfoxide (DMSO) a concentration range of 2–0.01 mg/mL. The amount of hematin present in each sample was calculated using a standard curve of hematin dissolved in 0.2 M NaOH. The absorbance was read using the ELISA reader at a wavelength of 405 nm. The effect of each sample against the production of  $\beta$ -hematin was calculated and compared with the negative control [17, 18].

2.9. Statistical Analysis. Data are expressed as mean-± standard deviation (SD).  $IC_{50}$  values were calculated using Probit Analysis. Statistical significance was determined by Kruskal–Wallis nonparametric independent *t*-test and ANOVA (*one-way*).

#### 3. Results and Discussion

*H. annuus* has been planted widely in Indonesia and long been used traditionally as anti-inflammatory, antimalarial, antiasthma, antioxidant, antitumor, and antimicrobial agent. It has been reported that several chemical compounds were already isolated and identified from various parts of this plant, such as heliangolides (sesquiterpene lactones),  $\alpha$ -pinene, sabinene (monoterpene), helikauranoside (diterpene), and alkaloid and phenolic group in the leaf part; helianthoside (triterpene) and saponin group in the flower part; fatty acid, tocopherol, tannin, and polyphenol group in the seed part; alkaloid and phenolic group in the stem and root parts [1]. Extraction yield from each part of *H. annuus* plants macerated with 96% ethanol is shown in Table 1.

In vitro screening to observe *P. falciparum* inhibition activity of the plant extract with IC<sub>50</sub> value less than  $10 \mu g/$ mL is an important primary step in the development of new antimalarial drugs. Plant extracts showing IC<sub>50</sub> values  $\leq 10 \mu g/mL$  can be considered to be active, IC<sub>50</sub> values in the range  $10 < IC_{50} \leq 25 \mu g/mL$  can be considered to be moderately active, and those exhibiting IC<sub>50</sub> values >25  $\mu g/mL$ can be considered to be inactive [19]. IC<sub>50</sub> values of 96% ethanol extract of various *H. annuus* plant parts are shown in Table 2. Root extract exhibits the highest *in vitro* antimalarial activity, followed by leaf and flower extracts with an IC<sub>50</sub> value of  $2.3 \pm 1.4$ ,  $4.3 \pm 2.2$ , and  $4.8 \pm 0.0 \mu g/mL$ , respectively.

*In vivo* antimalarial activity was also determined for each extract from various parts of *H. annuus* plants, and the results are shown in Table 3. Ethanol extract of root exhibits the highest percentage inhibition against *P. berghei*, followed by leaf extract with the percentage inhibition of  $63.6 \pm 8.0$  and  $59.3 \pm 13.2$ , respectively.

Method and criteria are varied among the treatment groups examining antimalarial potency of plants by using the rodent animal model. *P. berghei*-infected mice given orally 50–250 mg/kg/day of extract exhibiting inhibition percentage >60% are considered to be active or very active, and those exhibiting inhibition percentage >30% are considered to be moderately active [20–24]. In this research, oral

TABLE 1: Extraction yield from various parts of *H. annuus* plants.

H. annuus plant parts	Extraction yield (%)
Roots	2.1
Stems	5.0
Seeds	2.9
Flowers	6.7
Leaves	4.4

administration at a dose of 100 mg/kg/day of ethanol *H. annuus* extract is used as an initial experiment and observation of parasite growth up to day 4 using mice model.

Based on the first screening of *in vivo* assay, it is shown that *H. annuus* root extract has the highest activity. Thus, the experiment is continued to assess curative and prophylaxis antimalarial activity of the ethanol root extract of *H. annuus*.

In *in vivo* curative assay, *P. berghei*-infected mice are treated orally with 96% ethanol root extract at a dose of 1, 10, 100, and 250 mg/kg. The results of the 4-day suppressive test show that the ethanol extract of *H. annuus* root has an  $ED_{50}$  value of  $10.6 \pm 0.2$  mg/kg (Table 4). According to Munoz et al. [25], antimalarial activity can be categorized based on the  $ED_{50}$  value, where  $ED_{50} < 100$  mg/kg is considered to have very good activity.

In prophylactic effect evaluation of 96% ethanol *H. annuus* root extract, mice are given a sample orally for 4 days before inoculating with the parasite. The results (see Figure 1) show that the percentage of inhibition parasitaemia in mice treated with the extract at a dose of 400 mg/kg is higher than that in those treated with 800 mg/kg. Despite that, this result is still lower than that of doxycycline, a standard drug for prophylactic antimalarial in Indonesia.

The 400 mg/kg dose group shows the highest percentage of prophylactic inhibition (79.2%) at day 3, and it declines to 62.5% at a dose of 800 mg/kg. Calabrese and Baldwin [26] report that the upside-down U-curve in the drug activity assessment at different doses may indicate the occurrence of the hormetic effect, which points out to the toxicity of the drug. Aside from the declining percentage of inhibition, the low mean survival time at a dose of 800 mg/kg, compared to 200 and 400 mg/kg doses, indicates that the *H. annuus* root extract at high dose (800 mg/kg) tends to have toxicity.

The results of Kruskal–Wallis nonparametric independent *t*-test and *one-way* ANOVA analysis show that there are significant differences (p value < 0.05) in inhibition percentage of the positive control group compared with all the sample groups and the negative control group. There is no significant difference between 100, 200, 400, and 800 mg/ kg doses.

Figure 1 shows that, 96 hours or the fourth day after parasite inoculation, there is an increase in the parasitic growth in the negative dose and control group, whereas in the doxycycline group the parasite growth is relatively stable, which is below 3%. This is thought to be related to the halflife of doxycycline which ranges from 12 to 22 hours [15, 27, 28] allowing doxycycline to last longer in the body and inhibit the growth of parasites. It is in contrast to extracts or traditional medicines that tend to have a short halflife, such as artemisinin and its derivatives [29, 30]. Based on

II. autore alant norte		% inhibition	at each concentrat	ion (µg/mL)		IC (ualmal)
H. annuus plant parts	100	10	1	0.1	0.01	$IC_{50}$ (µg/mL)
Roots	$86.6 \pm 1.7$	$73.3 \pm 6.9$	$32.0 \pm 3.7$	$22.3\pm0.0$	$7.3 \pm 7.4$	$2.3 \pm 1.4$
Stems	$64.4 \pm 4.6$	$56.4 \pm 1.1$	$30.7 \pm 7.7$	$18.8\pm4.9$	0	$10.2 \pm 5.0$
Seeds	$84.4\pm1.0$	$22.2 \pm 6.9$	$14.2 \pm 3.9$	$6.2 \pm 10.3$	0	$19.3 \pm 5.5$
Flowers	$85.7 \pm 8.7$	$48.4 \pm 2.6$	$32.0 \pm 2.9$	$19.3 \pm 8.7$	0	$4.8 \pm 0.0$
Leaves	$96.3 \pm 1.8$	$47.1\pm4.7$	$24.3 \pm 11.7$	$16.5 \pm 6.2$	$7.0 \pm 1.0$	$4.3 \pm 2.2$

TABLE 2: IC<sub>50</sub> values of 96% ethanol extract of various parts of *H. annuus* plants against *P. falciparum* strain 3D7.

TABLE 3: Mean percentage of parasitaemia, growth, and inhibition in *P. berghei*-infected mice treated with 96% ethanol *H. annuus* extract at a dose of 100 mg/kg orally once a day for 4 days.

	Mean % p	parasitaemia	Mana 0/ amazatla	Mean % inhibition
H. annuus plant parts	Day 0	Day 4	Mean % growth	Mean % inhibition
Roots	$0.9 \pm 0.2$	$4.6 \pm 1.0$	$3.7 \pm 0.8$	$63.6 \pm 8.0$
Stems	$1.2 \pm 0.2$	$7.3 \pm 1.0$	$6.1 \pm 0.8$	$40.3 \pm 8.2$
Seeds	$1.0 \pm 0.2$	$7.1 \pm 0.5$	$6.0 \pm 0.4$	$41.5 \pm 4.4$
Flowers	$1.2 \pm 0.5$	$7.8 \pm 0.4$	$6.6 \pm 0.5$	$35.9 \pm 4.6$
Leaves	$0.9 \pm 0.2$	$5.1 \pm 1.5$	$4.2 \pm 1.4$	$59.3 \pm 13.2$
Na CMC	$1.6 \pm 0.3$	$11.8\pm0.9$	$10.3\pm0.9$	

TABLE 4: Mean percentage of parasitaemia, growth, and inhibition against *P. berghei* of 96% ethanol *H. annuus* root extract compared with control.

Sample	Dose (mg/kg)		an % itaemia	Mean % growth	Mean % inhibition	ED <sub>50</sub> (mg/kg)
		$D_0$	$D_4$			
	1	$1.1\pm0.1$	$26.2\pm1.4$	$6.3 \pm 0.4$	$35.8 \pm 4.7$	
96% ethanol extract of <i>H. annuus</i> root	10	$1.0 \pm 0.2$	$21.2\pm0.9$	$5.1 \pm 0.2$	$48.3\pm2.8$	$10.6 \pm 0.2$
90% ethallor extract of <i>H. unnuus</i> 100t	100	$1.0\pm0.1$	$15.4 \pm 1.7$	$3.6 \pm 0.4$	$64.0 \pm 5.3$	$10.0 \pm 0.2$
	250	$1.2 \pm 0.4$	$12.0\pm1.8$	$2.7 \pm 0.4$	$72.3 \pm 5.3$	
Na CMC		$1.2\pm0.3$	$40.3\pm6.1$	$9.8 \pm 1.5$		




FIGURE 1: Percentage of parasite growth during seven days after inoculation with parasites on *in vivo* prophylaxis assay of 96% ethanol extract of *H. annuus* roots. Average values and standard deviations from five mice per drug/dose are also shown. p value <0.05. EEHA = ethanolic extract of *H. annuus*.

#### Evidence-Based Complementary and Alternative Medicine

Sample	Concentration (mg/mL)	Mean value of hematin (mM)	Mean % inhibition	IC <sub>50</sub> (mg/mL)
Negative control		$121.0 \pm 2.6$	_	
e	2.00	$34.2 \pm 1.2$	$71.7 \pm 1.0$	
	1.00	$44.6 \pm 1.2$	$63.1 \pm 1.0$	
96% ethanol extract of root	0.50	$58.3 \pm 1.1$	$51.8 \pm 0.9$	04+00
96% ethanol extract of root	0.25	$67.6 \pm 1.3$	$44.1 \pm 1.1$	$0.4 \pm 0.0$
	0.10	$81.8 \pm 1.3$	$32.3 \pm 1.1$	
	0.01	$99.8 \pm 2.2$	$17.5 \pm 1.8$	
	2.00	$61.6 \pm 1.4$	$49.1 \pm 1.1$	
	1.00	$71.0 \pm 1.2$	$41.3 \pm 1.0$	
0.60 other all entry at a formal	0.50	$84.9 \pm 3.3$	$29.8 \pm 2.8$	24+02
96% ethanol extract of seed	0.25	$97.3 \pm 2.3$	$19.6 \pm 1.9$	$2.4 \pm 0.2$
	0.10	$105.5 \pm 1.3$	$12.8 \pm 1.1$	
	0.01	$114.1 \pm 1.8$	$5.7 \pm 1.5$	
	2.00	$46.8 \pm 1.1$	$61.4 \pm 0.9$	
	1.00	$55.7 \pm 1.3$	$53.9 \pm 1.1$	
O(0) at $1$ and $1$ and $1$ and $1$	0.50	$68.4 \pm 0.9$	$43.4 \pm 0.7$	0.0 + 0.1
96% ethanol extract of flower	0.25	$81.8 \pm 0.9$	$32.4 \pm 0.7$	$0.9 \pm 0.1$
	0.10	$89.8 \pm 0.9$	$25.8 \pm 0.8$	
	0.01	$99.3 \pm 1.2$	$17.9 \pm 1.0$	
	2.00	$38.6 \pm 0.9$	$68.1 \pm 0.7$	
	1.00	$48.9 \pm 0.8$	$59.6 \pm 0.7$	
O(0) other all east as the floor	0.50	$62.0 \pm 1.1$	$48.7\pm0.9$	05.00
96% ethanol extract of leaf	0.25	$75.5 \pm 1.4$	$37.6 \pm 1.1$	$0.5 \pm 0.0$
	0.10	$83.5 \pm 0.6$	$31.0 \pm 0.5$	
	0.01	$98.1 \pm 0.9$	$18.9\pm0.7$	
	2.00	$140.1 \pm 9.2$	$53.7 \pm 3.1$	
	1.00	$179.8 \pm 5.6$	$40.6 \pm 1.8$	
	0.50	$206.3 \pm 8.3$	$31.8 \pm 2.8$	10.05
96% ethanol extract of stem	0.25	$241.8 \pm 3.6$	$20.1 \pm 1.2$	$1.9 \pm 0.5$
	0.10	$264.7 \pm 3.6$	$12.5 \pm 1.2$	
	0.01	$288.0 \pm 5.5$	$4.8 \pm 1.8$	
	2.00	$40.4 \pm 2.1$	$66.6 \pm 1.7$	
	1.00	$50.9 \pm 0.6$	$57.9 \pm 0.5$	
	0.50	$64.3 \pm 0.9$	$46.8 \pm 0.7$	0 6 0 5
Chloroquine diphosphate	0.25	$77.0 \pm 0.8$	$36.3 \pm 0.7$	$0.6 \pm 0.0$
	0.10	$85.3 \pm 1.2$	$29.4 \pm 1.0$	
	0.01	$94.6 \pm 0.7$	$21.8 \pm 0.6$	

the antimalarial test results of *H. annuus* root *in vivo*, it can be concluded that the 96% ethanol extract of *H. annuus* root has more potential activities as curative antimalarial than prophylactic.

One of the potential biochemical targets for the development of new antimalarial drugs is heme detoxification. The results of heme detoxification inhibition assay (see Table 5) show that the 96% ethanol extract of *H. annuus* root ( $IC_{50} = 0.4 \pm 0.0 \text{ mg/mL}$ ) and leaf ( $IC_{50} = 0.5 \pm 0.0 \text{ mg/mL}$ ) has higher activity than chloroquine diphosphate, a standard antimalarial drug ( $IC_{50} = 0.6 \pm 0.0 \text{ mg/mL}$ ).

It was reported that free heme is toxic to parasites as it causes lysis of the parasite vacuolar membrane [31]. Thus, malaria parasites develop heme detoxification mechanism to change the toxic heme into a harmless one. The inhibition of heme detoxification leads to growth disorder and malaria parasites mortality as a result of membrane lysis and activity disorder of some enzymes [6–9].

Based on the entire assay undertaken in this research, it is established that the ethanol extract of *H. annuus* root shows the highest antimalarial activity among the other parts of plants, either in *in vitro*, *in vivo*, or in heme detoxification inhibition assay. Therefore, the ethanol extract of *H. annuus* root is a potential source of new antimalarial drugs from natural resources.

#### 4. Conclusion

Based on the results of the study, they show that 96% ethanol extract of *H. annuus* root has the highest antimalarial activity compared to stems, seeds, flowers, and leaves of *H. annuus*. 96% ethanol extract of *H. annuus* root has more potential activity as a curative antimalarial drug than a prophylactic one. Similarly, for the antimalarial mechanism in inhibiting heme detoxification, 96% ethanol extract of *H. annuus* root has the greatest inhibitory activity compared

to the other parts of *H. annuus*; even the inhibition is greater than chloroquine, a standard drug. So, it can be concluded that the 96% ethanol extract of *H. annuus* root contains a potential antimalarial substance which is a new source for the development of a new plant-based antimalarial agent.

#### **Data Availability**

All data are included within the manuscript.

#### **Conflicts of Interest**

The authors declare that they have no conflicts of interest.

#### Acknowledgments

The authors would like to thank "Riset Mandat" of Universitas Airlangga Scheme for financial support.

#### References

- S. Saini and S. Sharma, "Helianthus annuus (Asteracea): a review," International Journal of Pharma Professional's Research, vol. 2, no. 4, pp. 381–386, 2011.
- [2] N. H. Rakotoarivelo, F. Rakotoarivony, A. V. Ramarosandratana et al., "Medicinal plants used to treat the most frequent diseases encountered in Ambalabe rural community, Eastern Madagascar," *Journal of Ethnobiology and Ethnomedicine*, vol. 11, no. 1, p. 68, 2015.
- [3] R. Muti'ah, E. K. Hayati, and Khairunnisak, "The effectivity of ethanolic extract sunflower leaves (Helianthus annuus) as anti-malarial agent against Plasmodium berghei," in *Proceedingsof the International Conference, The 4th Green Technology Faculty of Science and Technology*, Islamic of University State Maulana Malik Ibrahim Malang, Malang, Indonesia, November 2013.
- [4] K. Ngibad, "The effectiveness of the combination of ethanol extract of sunflower leaves (*Helianthus annuus*) and antinganting (*Acalypha indica* Linn) as an antimalarial in vivo," *Journal of Galician Pharmacy*, vol. 5, no. 1, pp. 12–19, 2019.
- [5] E. M. Intisar, E. K. Hassan, A. M. Salah et al., "Anti-malarial activity of some medicinal Sudanese plants," *Journal of Forest Products and Industries*, vol. 3, no. 6, pp. 236–240, 2014.
- [6] I. W. Sherman, Malaria, Parasite Biology, Pathogenesis and Protection, ASM Press, Washington, DC, USA, 1998.
- [7] H. L. Ziegler, D. Staerk, J. Christensen, L. Hviid, H. Hagerstrand, and J. W. Jaroszewski, "In vitro *Plasmodium falciparum* drug sensitivity assay: inhibition of parasite growth by incorporation of stomatocytogenic amphiphiles into erythrocyte membrane," *Antimicrobial Agents and Chemotherapy*, vol. 46, no. 5, pp. 1441–1446, 2002.
- [8] S. Auparakkitanon, W. Noonpakdee, R. K. Ralph, W. A. Denny, and P. Wilairat, "Antimalarial 9-anilinoacridine compound directed at hematin," *Antimicrobial Agents and Chemotherapy*, vol. 47, no. 12, pp. 3708–3712, 2003.
- [9] B. Tekwani and L. Walker, "Targeting the hemozoin synthesis pathway for the new antimalarial drug discovery: technologies for in vitro β-hematin formation assay," *Combinatorial Chemistry & High Throughput Screening*, vol. 8, no. 1, pp. 63–79, 2005.
- [10] A. V. Pandey, H. Bisht, V. K. Babbarwal, J. Srivastava, K. C. Pandey, and V. S. Chauhan, "Mechanism of malarial

haem detoxification inhibition by chloroquine," *Biochemical Journal*, vol. 355, no. 2, pp. 333–338, 2001.

- [11] A. V. Pandey, B. L. Tekwani, R. L. Singh, and V. S. Chauhan, "Artemisinin, and endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite," *Journal of Biological Chemistry*, vol. 274, no. 27, pp. 19383–19388, 1999.
- [12] W. Trager and J. Jensen, "Human malaria parasites in continuous culture," *Science*, vol. 193, no. 4254, pp. 673–675, 1976.
- [13] W. Ekasari, T. S. Wahyuni, H. Arwati, and N. T. Putri, "Determination of effective dose of antimalarial from *Cassia spectabilis* leaf ethanol extract in *Plasmodium berghei*-infected mice," *African Journal of Infectious Disease*, vol. 12, no. suppl. 1, pp. 110–115, 2018.
- [14] W. Peters, J. H. Portus, and B. L. Robinson, "The chemotherapy of rodent malaria. XXII. The value of drug-resistant strains of *P. berghei* in screening for blood schizontocidal activity," *Annals of Tropical Medicine & Parasitology*, vol. 69, no. 2, pp. 155–171, 1975.
- [15] K. R. Tan, A. J. Magill, P. M. Arguin, and M. E. Parise, "Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis," *The American Journal of Tropical Medicine and Hygiene*, vol. 84, no. 4, pp. 517–531, 2011.
- [16] N. Basilico, E. Pagani, D. Monti et al., "A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs," *Journal of Antimicrobial Chemotherapy*, vol. 42, no. 1, pp. 55–60, 1998.
- [17] T. S. Macedo, L. Colina-Vegas, M. Da Paixão et al., "Chloroquine-containing organoruthenium complexes are fastacting multistage antimalarial agents," *Parasitology*, vol. 143, no. 12, pp. 1543–1556, 2016.
- [18] S. Joshi, R. Munshi, G. Talele et al., "An experimental in vitro study to evaluate the antimalarial activity of select homeopathy preparations," *International Journal of Medical and Health Research*, vol. 3, no. 7, pp. 65–68, 2017.
- [19] R. B. S. Lima, L. F. Rocha e Silva, M. R. S. Melo et al., "In vitro and in vivo anti-malarial activity of plants from the Brazilian Amazon," *Malaria Journal*, vol. 14, no. 1, p. 508, 2015.
- [20] L. F. Rocha e Silva, K. L. Nogueira, A. C. da Silva Pinto et al., "In vivo antimalarial activity and mechanisms of action of 4nerolidylcatechol derivatives," *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 6, pp. 3271–3280, 2015.
- [21] H. C. Upadhyay, B. S. Sisodia, J. Agrawal, A. Pal, M. P. Darokar, and S. K. Srivastava, "Antimalarial potential of extracts and isolated compounds from four species of genus *Ammannia*," *Medicinal Chemistry Research*, vol. 23, no. 2, pp. 870–876, 2014.
- [22] M. F. Musila, S. F. Dossaji, J. M. Nguta, C. W. Lukhoba, and J. M. Munyao, "*In vivo* antimalarial activity, toxicity and phytochemical screening of selected antimalarial plants," *Journal of Ethnopharmacology*, vol. 146, no. 2, pp. 557–561, 2014.
- [23] J. M. Nguta and J. M. Mbaria, "Brine shrimp toxicity and antimalarial activity of some plants traditionally used in treatment of malaria in Msambweni district of Kenya," *Journal of Ethnopharmacology*, vol. 148, no. 3, pp. 988–992, 2013.
- [24] J. W. Gathirwa, G. M. Rukunga, P. G. Mwitari et al., "Traditional herbal antimalarial therapy in Kilifi district, Kenya," *Journal of Ethnopharmacology*, vol. 134, no. 2, pp. 434–442, 2011.

- [25] V. Muñoz, M. Sauvain, G. Bourdy et al., "The search for natural bioactive compounds through a multidisciplinary approach in Bolivia. Part II. Antimalarial activity of some plants used by Mosetene Indians," *Journal of Ethnopharmacology*, vol. 69, no. 2, pp. 139–155, 2000.
- [26] E. J. Calabrese and L. A. Baldwin, "Hormesis: U-shaped dose responses and their centrality in toxicology," *Trends in Pharmacological Sciences*, vol. 22, no. 6, pp. 285–291, 2001.
- [27] B. A. Cunha, J. B. Comer, and M. Jonas, "The tetracyclines," *Medical Clinics of North America*, vol. 66, no. 1, pp. 293–302, 1982.
- [28] P. G. Welling, P. A. Koch, C. C. Lau, and W. A. Craig, "Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects," *Antimicrobial Agents and Chemotherapy*, vol. 11, no. 3, pp. 462–469, 1977.
- [29] Z. Guo, "Artemisinin anti-malarial drugs in China," Acta *Pharmaceutica Sinica B*, vol. 6, no. 2, pp. 115–124, 2016.
- [30] K. Karunamoorthi, S. Sabesan, K. Jegajeevanram, and J. Vijayalakshmi, "Role of traditional antimalarial plants in the battle against the global malaria burden," *Vector-Borne and Zoonotic Diseases*, vol. 13, no. 8, pp. 521–544, 2013.
- [31] A. C. Chou and C. D. Fitch, "Mechanism of hemolysis induced by ferriprotoporphyrin IX," *Journal of Clinical Investigation*, vol. 68, no. 3, pp. 672–677, 1981.



**KOMISI ETIK PENELITIAN** FAKULTAS KEDOKTERAN HEWAN UNIVERSITAS AIRLANGGA Animal Care and Use Committee (ACUC)

### **KETERANGAN KELAIKAN ETIK**

"ETHICAL CLEARENCE"

#### No: 2.KE.119.07.2018

#### KOMISI ETIK PENELITIAN (ANIMAL CARE AND USE COMMITTEE) FAKULTAS KEDOKTERAN HEWAN UNIVERSITAS AIRLANGGA SURABAYA, TELAH MEMPELAJARI SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA DENGAN INI MENYATAKAN BAHWA :

PENELITIAN BERJUDUL

: Aktivitas Prolfilaksis Antimalaria Ekstrak Etanol 96% Akar Heliathus annuus L Secara In Vivo Pada Mencit Balb/C

PENELITI UTAMA

UNIT/LEMBAGA/TEMPAT : Departemen Farmakognosi dan Fitokimia Fakultas Farmasi Universitas Airlangga

DINYATAKAN

PENELITIAN

: LAIK ETIK

: Zelmira Amanda


Surabaya, 19 Juli 2018

Mengetahui, Dekan FKH-Unair Prof. Dr. Pudji Srianto, M.Kes., Drh. NIP. 195601051986011001

Ketua,

Dr. Nusdianto Triakoso, M.P., Drh. NIP. 196805051997021001

## Bukti – Subject Area and Category, Quartile dan SJR Tahun Terbit (2019)



# Bukti – Scopus Coverage, Publisher dan ISSN

Scopus Preview	Q Author Search Sources	⑦	Sign in
Source details		Fee	dback 🔪 Compare sources >
Evidence-based Complementary and A Open Access ① Scopus coverage years: from 2005 to Present	Iternative Medicine	CiteScore 3.2	2021
Publisher: Hindawi ISSN: 1741-427X E-ISSN: 1741-4288 Subject area: (Medicine: Complementary and Alternative Medicine)		SJR 2021 0.461	٥
Source type: Journal	list Source Homepage	SNIP 202 0.901	(i)
CiteScore CiteScore rank & trend Scopus content co	overage		
i Improved CiteScore methodology CiteScore 2021 counts the citations received in 2018-2021 to an papers published in 2018-2021, and divides this by the number	61 01 (MAN) 10 A		×
$3.2 = \frac{13,705 \text{ Citations } 2018 - 2021}{4,268 \text{ Documents } 2018 - 2021} 2.8$	$8 = \frac{11,432 \text{ Citations to date}}{4,118 \text{ Documents to date}}$		
CiteScore rank 2021 ① Category Rank Percentile			
Medicine Complementary and #26/93 72nd Alternative Medicine			

Tier
Тор
I
<u>k</u> ti
Bu

									nago:	SCIMAGO	SCIMAGO INSTITUTIONS RANKINGS	IS RANKING	•
	SJR Scimago Journal & Country Rank	untry Ran	~					Enter .	Enter Journal Title, ISSN or Publisher Name	SN or Publish	er Name	ď	
		Home	Journal Rankings	ankings	Country Rankings		Viz Tools	Help Ab	About Us				
	Medicine	Complementary and Alternative Medicine	tary and Aedicine	>	United States	>	Journals	als	>	2019		>	
>	Only Open Access Journals Only SciELO Journals Only WoS Journals	urnals 0	or Sow Vinc	urnals ?			Displa	Display journals with at least 0	at least 0	Citable Docs. (3years)	s. (3years) 🗸	Apply	
											od ➡	Download data	
											1 - 7 of 7	f7 < >	
	Title	Type	<b>↓</b> SJR	H index	Total Docs. (2019)	Total Docs. (3years)	Total Refs. (2019)	Total Cites (3years)	s Citable Docs. ) (3years)	Cite	Ref	Ref. / Doc. (2019)	
-	Integrative Cancer Therapies <mark>3</mark>	journal	0.708 Q1	63	121	253	5541	636		244	2.46	45.79	
2	Complementary Therapies in Medicine <mark>8</mark>	journal	0.576 Q1	69	285	435	12040	1043		415	2.08	42.25	
m	Evidence-based Complementary and Alternative Medicine <mark>3</mark>	journal	0.510 Q1	100	786	2065	36451	4190		2022	1.83	46.38	
4	American Journal of Clinical Hypnosis <mark>8</mark>	journal	0.266 Q2	29	6	113	457	48		86	0.33	50.78	Þ